Thomas Rademacher MD, PHD - CEO Emergex

Send us Fan MailIn this episode of Life Science Success, my guest is Dr. Thomas Rademacher. Professor Rademacher, MD, PhD, co-founded Emergex and has served as CEO since the Company’s formation. He is an Emeritus Professor of Molecular Medicine at University College London (UCL) and a serial entrepreneur.   Dr. Thomas Rademacher, MD, PhD, is the co-founder and CEO of Emergex, with a background as an Emeritus Professor of Molecular Medicine at the University College of London and a serial entrepreneur. His career has oscillated between academic and entrepreneurial roles, adhering to the philosophy of not staying in the same job for more than ten years. Rademacher's academic foundation in hardcore biochemistry was established during his PhD at the University of Wisconsin Madison. This rigorous training in biochemistry has been a cornerstone throughout his career, enabling him to navigate and innovate in the complex field of molecular medicine. His work has significantly contributed to the field of monoclonal antibodies, starting with foundational research at Oxford and involving the use of Chinese hamster ovary (CHO) cells. This work was pivotal for the development of recombinant proteins and monoclonal antibodies, leading to advancements in medicine. Rademacher has been involved in groundbreaking research and entrepreneurial ventures, including the Glycobiology Institute, which attracted interest from major corporations like Monsanto. His work has led to significant scientific advancements and the formation of companies that have had substantial impacts on the medical and biotechnological landscapes. He is currently focused on challenges in vaccinology and immunology, particularly in developing vaccines that activate the cellular immune response to fight viral infections effectively. Rademacher's innovative approach involves utilizing quantum-confined gold clusters and micro-needle technology to enhance vaccine delivery and efficacy.